Personalis Stock Today
| PSNL Stock | USD 3.63 0.06 1.68% |
PerformanceWeak
| Odds Of DistressAverage
|
Personalis is selling for 3.63 as of the 17th of March 2025. This is a 1.68 percent increase since the beginning of the trading day. The stock's lowest day price was 3.55. Personalis has 54 percent odds of going through some form of financial distress in the next two years and did not have a very good performance for investor during the last 90 trading days. Note, on June 4, 2020, Representative Brian Mast of US Congress acquired $15k to $50k worth of Personalis's common stock.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 20th of June 2019 | Category Healthcare | Classification Health Care |
Personalis, Inc. operates as a cancer genomics company worldwide. Personalis, Inc. was incorporated in 2011 and is headquartered in Menlo Park, California. Personalis operates under Diagnostics Research classification in the United States and is traded on NASDAQ Exchange. The company has 88.26 M outstanding shares of which 3.88 M shares are at this time shorted by private and institutional investors with about 3.47 trading days to cover. More on Personalis
Moving together with Personalis Stock
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores
Personalis Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| CEO President | Christopher Hall | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Life Sciences Tools & Services, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Biotechnology, NASDAQ Composite, NASDAQ Health Care, Health Care, Life Sciences Tools & Services, Diagnostics & Research, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsPersonalis can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Personalis' financial leverage. It provides some insight into what part of Personalis' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Personalis (PSNL) is traded on NASDAQ Exchange in USA. It is located in 6600 Dumbarton Circle, Fremont, CA, United States, 94555 and employs 228 people. Personalis is listed under Life Sciences Tools & Services category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 320.4 M. Personalis conducts business under Life Sciences Tools & Services sector and is part of Health Care industry. The entity has 88.26 M outstanding shares of which 3.88 M shares are at this time shorted by private and institutional investors with about 3.47 trading days to cover.
Personalis currently holds about 233.49 M in cash with (45.15 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.09, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Personalis Probability Of Bankruptcy
Ownership AllocationPersonalis owns a total of 88.26 Million outstanding shares. Personalis has significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. On June 4, 2020, Representative Brian Mast of US Congress acquired $15k to $50k worth of Personalis's common stock.
Check Personalis Ownership Details
Personalis Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Sumitomo Mitsui Trust Group Inc | 2024-12-31 | 733.3 K | |
| Geode Capital Management, Llc | 2024-12-31 | 498.1 K | |
| State Treasurer State Of Michigan | 2024-12-31 | 493.8 K | |
| Wellington Shields Capital Mgmt Llc | 2024-12-31 | 431.2 K | |
| Dimensional Fund Advisors, Inc. | 2024-12-31 | 410.1 K | |
| Jane Street Group Llc | 2024-12-31 | 401.3 K | |
| Qube Research & Technologies | 2024-12-31 | 398.5 K | |
| Jacobs Levy Equity Management, Inc. | 2024-12-31 | 388.5 K | |
| Aberdeen Group Plc | 2024-12-31 | 297.9 K | |
| Merck & Co Inc | 2024-12-31 | 14 M | |
| Lightspeed Management Co Llc | 2024-12-31 | 8.2 M |
Personalis Historical Income Statement
Personalis Stock Against Markets
Personalis Corporate Management
| Stephen JD | Senior Officer | Profile | |
| Christian Haudenschild | Senior Operations | Profile | |
| DPHIL FRCP | CoFounder Board | Profile | |
| Carol Tillis | VP Admin | Profile | |
| MS MD | Executive Officer | Profile | |
| MD MS | VP Officer | Profile |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Personalis. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. For more information on how to buy Personalis Stock please use our How to buy in Personalis Stock guide.You can also try the Idea Analyzer module to analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas.
Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Personalis. If investors know Personalis will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Personalis listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.37) | Revenue Per Share | Quarterly Revenue Growth (0.15) | Return On Assets | Return On Equity |
The market value of Personalis is measured differently than its book value, which is the value of Personalis that is recorded on the company's balance sheet. Investors also form their own opinion of Personalis' value that differs from its market value or its book value, called intrinsic value, which is Personalis' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Personalis' market value can be influenced by many factors that don't directly affect Personalis' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Personalis' value and its price as these two are different measures arrived at by different means. Investors typically determine if Personalis is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Personalis' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.